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Abstract: The treatment of brain disorders is one of the greatest challenges in drug delivery 
because of a variety of main barriers in effective drug transport and maintaining therapeutic 
concentrations in the brain for a prolonged period. The objective of this study was delivery 
of valproic acid (VPA) to the brain by intranasal route. For this purpose, nanostructured lipid 
carriers (NLCs) were prepared by solvent diffusion method followed by ultrasonication and 
characterized for size, zeta potential, drug-loading percentage, and release. Six groups of rats 
each containing six animals received drug-loaded NLCs intraperitoneally (IP) or intranasally. 
Brain responses were then examined by using maximal electroshock (MES). The hind limb tonic 
extension:flexion inhibition ratio was measured at 15-, 30-, 60-, 90-, and 120-minute intervals. 
The drug concentration was also measured in plasma and brain at the most   protective point 
using gas chromatography method. The particle size of NLCs was 154 ± 16 nm with drug-
loading percentage of 47% ± 0.8% and drug release of 75% ± 1.9% after 21 days. In vivo results 
showed that there was a significant difference between protective effects of NLCs of VPA and 
control group 15, 30, 60, and 90 minutes after treatment via intranasal route (P , 0.05). Similar 
protective effect was observed in rats treated with NLCs of VPA in intranasal route and positive 
control in IP route (P . 0.05). Results of drug determination in brain and plasma showed that 
brain:plasma concentration ratio was much higher after intranasal administration of NLCs of 
VPA than the positive control group (IP route). In conclusion, intranasal administration of NLCs 
of VPA provided a better protection against MES seizure.
Keywords: maximal electroshock, nano lipid carriers, intranasal route, valproic acid, brain 
delivery
Introduction
General methods that can enhance drug delivery to the brain are of great interest. 
A   noninvasive technique for drug delivery to the brain is through intranasal admin-
istration. Intranasal drug administration was shown to present a safe and acceptable 
alternative to parenteral administration of various drugs that offers rapid absorption to 
the systemic blood, avoiding first-pass metabolism in the gut wall and the liver. Fur-
ther, several studies have shown a direct route of transport from the olfactory region 
to the central nervous system (CNS) in animal models, without prior absorption to the 
circulating blood.1 This neuronal connection constitutes a direct pathway to the brain.2 
However, it has been reported that the amount of drug which was delivered to the brain 
was very low indeed, with concentrations in the cerebrospinal fluid (CSF) and olfactory International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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lobes from 0.01% to 0.1% bioavailability and dependent on 
  characteristics of the molecule.3 Although the clinical potential 
of this delivery route still remains controversial, there is con-
siderable interest in exploring this route for the treatment of 
common intracerebral   diseases.4 A promising strategy for 
drug   delivery without any modification to the drug molecule 
is using   colloidal carriers such as nanoparticles. Lipid nano-
particles are interesting candidates for brain targeting, due to 
rapid uptake by the brain, bioacceptability, biodegradability, 
and less toxicity compared to the polymeric nanoparticles. 
Indeed, feasibility in scale-up and absence of burst effect 
make them promising carriers for drug delivery.5,6
Valproic acid (VPA) is widely used in the treatment 
of epilepsy, bipolar disorders, migraine, and cancer.7 
Administration of high doses of the drug is needed to   provide 
clinical effects because of inefficient delivery of VPA to the 
brain. The variety of drug interactions and side effects of 
VPA are due to long-term use of drug and its rather high 
daily dosage requirements, particularly in adolescents and 
young women.8 Based on the results found in a brain efflux 
index study, Scism et al9 estimated that the efflux clearance 
of VPA at the blood–brain barrier (BBB) was 2.7-fold greater 
than influx clearance compared to control animals. Therefore, 
lowering the dosage of administration is important and one of 
the main aims of the current study. VPA distribution in brain 
is less than that of other anticonvulsants, such as   phenytoin 
or phenobarbital via oral route. Possible mechanisms for this 
decreased distribution space in brain include a) increased 
plasma protein binding of valproate relative to the other 
anticonvulsants and b) asymmetric (BBB) transport of 
valproate such that the brain-to-blood flux exceeded the 
blood-to-brain flux.10,11
Three animal models which are commonly used in 
characterization of anticonvulsant drugs are the maximal 
  electroshock (MES) seizure test, pentylenetetrazol (PTZ) 
seizure test, and kindling. The MES and PTZ tests are   models 
of acute (reactive or provoked) seizures.12 The MES test, 
which is a widely used animal model, identifies the drug activ-
ity against generalized tonic–clonic and partial seizures.13,14
The aim of this study is to develop intranasal nanostructured 
lipid carriers (NLCs) of VPA for lowering the dosage and 
  providing prolonged action and evaluation of its efficacy against 
generalized tonic–clonic seizures by a simple study in rats.
Materials and methods
Materials
VPA was provided by Chemische Fabrik Berg GmbH 
(Bitterfeld, Germany). Cetyl palmitate (CP) (mp 46°C–53°C; 
Croda, Cowick Hall, UK), Poloxamer 188 (Sigma-Aldrich 
Chemie, Munich,   Germany), Soy lecithin S100 (Lipoid 
GMBH,   Ludwigshafen, Germany), and octyldodecanol (Sasol 
  Germany,   Hamburg, Germany) were used as received. Acetone, 
ethanol, high-pressure liquid   chromatography (HPLC) grade 
  acetonitrile, caproic acid, and chloroform were purchased from 
Merck Chemical Company   (Darmstadt,   Germany). All other 
chemicals and reagents were of   analytical grade.
Preparation of VPA-loaded NLc
NLCs of VPA were prepared by an emulsion–solvent diffusion 
and evaporation method followed by ultrasonication as 
reported earlier.15,16 Briefly, the hot lipid phase at 60°C, con-
taining 400 mg of CP, 100 mg of soy lecithin S100, 0.1 mL of 
octyldodecanol, and 400 mg of VPA, was dissolved in 10 mL 
of a mixture of three parts acetone and one part absolute etha-
nol in a water bath. The oily phase was then dispersed in 50 mL 
aqueous phase containing 1% Poloxamer 188 at 50°C and 
stirred for 1 minute at 2000 rpm. The resulting pre-emulsion 
was then ultrasonicated for 2 minutes using a probe sonicator 
(Bandelin Electronic, Berlin, Germany) by probe TT13 in 40% 
amplitude to produce oil in water (O/W) nanoemulsion. In the 
final step, the obtained nanoemulsion (O/W) was cooled down 
at room temperature while stirring at 600 rpm for about 1 hour. 
Optimization of the nanoparticle formulations was carried out 
using Taguchi screening design and Box–Behnken analysis 
as reported earlier by the authors.15,16
characterization of NLcs of VPA
Photon correlation spectroscopy (Zetasizer 3000; Malvern 
Instruments, Malvern UK) was used to measure size and 
zeta potential of all drug-loaded NLC samples. All samples 
were diluted (1:10) with deionized water to get optimum 
50–200 kilo counts per second for measurements. Z-average 
particle size, polydispersity index, and zeta potential were 
measured in triplicate.
Drug-loading percentage was determined by measuring 
the concentration of unentrapped free drug in aqueous 
medium.17 To do this, approximately 1.5 mL of the NLC 
dispersion was placed in microtubes, acidified to pH 1.5 
with HCl 1N, and centrifuged at 25,000 rpm for 30 minutes 
(Sigma 3K30;   Osterode am Harz, Germany). The aque-
ous medium was separated, and the amount of VPA in the 
aqueous phase was determined by a reversed-phase HPLC 
(Waters, Milford, MA), with UV detector, according to the 
procedure described by Kishore et al18 with modification. 
The analysis was performed at 210 nm using a Nova-pak, 
reversed-phase C18 column, 250 × 4.5 mm, employing a International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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mobile phase of 40% acetonitrile and 60% phosphate-
buffered solution (PBS) 0.02 M (pH 3), delivered at a flow 
rate of 1 mL/min.18 The retention time of the drug was found 
to be 10.0 ± 0.1 min. Data analysis and processing was car-
ried out using Millennium software (Version 32; Millenium, 
Milford, MA).
To determine the release rate of VPA from nanoparticles, 
3 mL of aqueous dispersion of each formulation was added to 
the dialysis bags with molecular weight cutoff of 12,400 Da, 
and the sealed bags were placed in a glass test tube containing 
100 mL PBS 0.1 M (pH 6) and 0.1% polysorbate 80 to 
  provide sink conditions with agitation of 200 rpm. Samples 
of 1 mL were withdrawn at predetermined time intervals of 
2, 24, 72, 96, 240, 336, and 504 hours (21 days) and replaced 
with fresh PBS and maintained at the same temperature. 
The content of VPA in the samples was determined by the 
described HPLC method.
Animals and study design
Male Wistar rats (body weight: 180–210 g) from animal house 
of the School of Pharmacy and Pharmaceutical   Sciences of 
Isfahan University of Medical Sciences were used for the 
in vivo studies. The animals were housed in colony cages 
with free access to standard chow pellets and water, under 
uniform housing in the environmentally controlled condi-
tions (22 ± 2°C, 12-hour light–dark cycle, and 55%–65% 
humidity), and placed in the laboratory for 4–6 days during 
the acclimatization period and during the course of the study. 
The animal study was approved by the guideline of the ethical 
committee of Isfahan University of Medical Sciences.
Experiments were performed between 11 am and 2 pm. 
The rats were divided into six experimental groups each 
comprising six animals. All animals underwent preliminary 
screening MES test, and only the responsive ones received 
drugs 48 hours after preliminary MES test. Electrical 
stimulation was performed via auricular electrodes (110 mA 
square wave with a 100 Hz current, 1 millisecond pulse 
duration, and 0.2 second shock duration) to produce tonic 
hind limb extension in more than 50% of rats.19 Electrodes 
were wetted with 0.9% normal saline to induce stimulation. 
The duration of hind limb flexion and extension was recorded, 
and extension:flexion (E:F) ratio was taken as a measure 
of seizure severity. The animals with an increased E:F 
ratio, related to the treated ones, were considered to exhibit 
more severe seizures.20 Intraperitoneal (IP) administration 
of phenytoin (90 mg/kg) was used as gold standard, and 
MES was carried out approximately 2 hours after injec-
tion. Table 1 shows the details of preparations and routes of 
administration of the study groups.
Drug administration
Prepared formulation of VPA was placed in dialysis bag 
with molecular weight cutoff of 12,400 Da in purified water 
with sink condition for about 24 hours in order to separate 
nanoparticles from free drugs adhered on their surface. 
Then, the amount of VPA loaded in the nanoparticles was 
  determined to obtain the required dose for administration. 
The solution of VPA as positive control was prepared using its 
sodium salt equivalent to the corrected dose of VPA in purified 
water. Control suspension of NLCs was prepared using the 
same method of NLC preparation without VPA. For intra-
nasal administration, 100 µL of drug solution was delivered 
in each nostril within a few minutes via 2 cm polyethylene 
tubing (outer diameter: 0.965 mm, inner diameter: 0.58 mm) 
attached to a Hamilton syringe, while the animal was held 
in a supine position under light ether anesthesia. The other 
groups were injected IP. Thereafter, rats were given shock in 
predetermined times (Table 1), and E:F ratio and the time 
that maximum protection obtained were recorded. Then, at 
the maximum protection time, the rats were sacrificed, and 
plasma and the whole hemisphere of brain tissue samples 
were prepared and processed according to the following meth-
ods and analyzed by gas chromatography (GC)   (Shimadzu 
17 A; Shimadzu Co., Kyoto, Japan).
Table 1 Preparations, dosage, routes, and times of administration of different preparations of VPA used in the different experimental 
groups
Experimental group Preparation Administered dose (mg/kg) Route of administration Timea (min)
1 controlb – Intranasal 15, 30, 60, 90, and 120
2 controlb – IP 15, 30, 60, 90, and 120
3 NLc of VPA 4 Intranasal 15, 30, 60, 90, and 120
4 NLc of VPA 20 IP 15, 30, 60, 90, and 120
5 sodium VPA solution 30c Intranasal 15, 30, 60, 90, and 120
6 sodium VPA solution 150c IP 15, 30, 60, 90, and 120
Notes: aTime between administration of valproate and electrical stimulation; bBlank contains all of the components of nanoparticles except VPA; cDosage is equivalent to VPA. 
Abbreviations: VPA, valproic acid; NLc, nanostructured lipid carrier; IP, intraperitoneal.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Blood and plasma sample preparation
The blood samples of about 3 mL were taken by slaughtering 
the animal when it was under ether anesthesia and transferred 
into a heparinized glass tube at 60 minutes after dosing. Blood 
samples were centrifuged for 15 minutes at 3000 rpm, and the 
separated plasma was stored at −20°C until analysis. Follow-
ing the completion of blood collection, the scull of the rat was 
opened after separation of the head, and the whole brain was 
collected. The brain samples were rinsed with normal saline and 
immediately stored at −70°C until analysis. In order to deter-
mine the concentration of VPA in the brain, one hemisphere 
was weighed and was homogenized in 0.5 mL of PBS.
Assay of VPA in plasma and brain tissue samples
VPA was assayed using a modified method of GC after 
extraction.21–23 Briefly, an exactly 200 µL sample of plasma 
was well mixed with 200 µL HCl (2 M) and 62 µg caproic 
acid (186 µg/mL in methanol) as internal standard using 
electrical vortex. The mixture was extracted for 2 minutes 
with 400 µL of chloroform and centrifuged at 3000 rpm for 
20 minutes. A total of 1.0 µL of bottom layer of the sample 
was injected into the GC. To 0.5 mL of the brain homogenate, 
0.5 mL of HCl 6N was added, and the mixture was extracted 
for 2 minutes with 600 µL chloroform   containing 37 µg 
  caproic acid (186 µg/mL in methanol) as internal   standard 
and centrifuged at 3000 rpm for 20 minutes. Finally, 1.0 µL 
of bottom layer of the sample was injected into the GC 
(detector: FID; column: 30 m × 0.53 mm, a wide bore 
  column 5 µm [TRB-G27 Teknokroma, Barcelona, Spain]). 
The column temperature was programmed as follows: 130°C 
at 10°C/min and isothermal at 240°C for 10 minutes. The 
detector temperature was 290°C, and injector tempera-
ture was 200°C. Helium was the carrier gas, air-hydrogen 
pressure for detection, column flow rate: 5.6 mL/min, split 
ratio: 5, linear velocity: 54, total flow: 35 mL/min. Retention 
times were 3.8 and 5.6 minutes for caproic acid and VPA, 
respectively. Calibration curves of VPA were prepared using 
plasma and brain tissue mixed with known amounts of the 
drug, utilizing its GC peak area ratios to the internal standard. 
Calibration curve of VPA was linear within the concentration 
range between 2 and 100 µg/mL (Y = 0.007X + 0.039, 
n = 5, r2 = 0.999). The mean extraction recovery of VPA 
from plasma and brain tissue homogenate was more than 
95.4% ± 5.7% and 90.4% ± 7.2%, respectively.
statistical analysis
The one-way analysis of variance and Tukey post hoc test 
were applied for determining the significance of differences 
in seizure protection effect between treatment, positive 
  control, and control groups, which was shown using reduction 
ratio of E:F between groups in each time. Unpaired Student’s 
t-test was used to compare mean protective effect of NLCs 
of VPA in intranasal route and sodium VPA solution in IP 
route. All data are expressed as means ± SD. P # 0.05 was 
considered statistically significant.
Results
The results of characterization of NLCs of VPA for size, 
  polydispersity index, zeta potential, drug release, and drug 
loading are shown in Table 2. Each value is the average of three 
replicates. IP administration of phenytoin (90 mg/kg), as gold 
standard, showed that none of the rats presented   extension, 
while in more than 50% of non-treated animals, extension 
was observed. Figure 1 shows the results of the effects of 
NLCs of VPA in comparison with sodium valproate   solution 
(positive control) and control NLCs   (without VPA) on MES 
seizure, which is assessed as the decrease of E:F ratio in 
intranasal route of administration. As this figure shows, there 
is a significant difference (P , 0.05) between protective 
effects of NLCs of VPA and control NLC 15, 30, 60, and 
90 minutes after intranasal administration as well as between 
NLCs of VPA and the positive control group 60 minutes after 
the drug administration via the intranasal route. The results 
of the determination of VPA concentration, in plasma and 
brain tissue after intranasal administration of NLCs of VPA 
and sodium valproate solution, revealed that brain:plasma 
ratio at 60 minutes was much higher with intranasal VPA in 
NLCs, while the administered dose was much less than that 
administered through other route (Table 3). Figure 2 shows 
the results of the effects of NLCs of VPA, positive control, 
and control NLC 15, 30, 60, 90, and 120 minutes after IP 
administration. There was a significant difference (P , 0.05) 
Table 2 composition and physical properties of the optimized NLcs of VPA
Cetyl 
palmitate 
(%)
Poloxamer 
188 (%)
Lipoid 
(%)
Octyldodecanol 
(%)
VPA  
(%)
Drug 
loading 
(%)
Particle 
size (nm)
Zeta 
potential 
(mV)
Drug release 
after 21 days 
(%)
Polydispersity 
index
0.8 1 0.2 0.2 0.8 47 ± 0.8 154 ± 16 −10 ± 0.5 75 ± 1.9 0.2 ± 0.1
Abbreviations: NLcs, nanostructured lipid carriers; VPA, valproic acid.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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between protective effect of NLC of VPA and control NLC 
30 min after administration. This result shows that sodium 
valproate solution presented higher protective effect than 
control NLC 15, 60, and 90 minutes after administration.
A t-test statistical analysis showed that there was no 
significant difference (P . 0.05) between the protective effect 
of NLCs of VPA in intranasal route and positive   control in IP 
route, as a systemic route of administration, at any time after 
administration (Figure 3). Results showed that protective effect 
of VPA nanostructures by intranasal route is similar to that of 
sodium valproate after systemic route of administration, while 
its dosage is significantly smaller than systemic route. Correla-
tion between MES protective effect of different preparations 
and brain:plasma concentration ratio at 60 minutes (the most 
protective time) revealed that intranasal administration of VPA 
nanostructures provided the same protective effect as sodium 
valproate solution after systemic administration, with a dose 
of about 37 times less than that administered by the IP route 
(Figure 4). This shows that brain/plasma concentration is 
higher in intranasal administration of NLCs of VPA.
Discussion
BBB is absent or very thin in diameter in the interphase of 
brain–olfactory nerve epithelium,24 so intranasal route was 
chosen in the present study to bypass the BBB and promote 
drug distribution into the brain. The incorporation of drugs into 
nanoparticles might be a promising approach, since   colloidal 
formulations were shown to protect drugs from degrading 
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Figure 1 comparison between the effect of sodium valproate solution positive control (30 mg/kg), NLcs of VPA (4 mg/kg), and control NLcs (without VPA) in nasal route 
of administration on MES seizure protection which was assessed as the decrease of extension:flexion (E:F) ratio (n = 6).
Notes: *Statistically significant difference (P , 0.05) with respect to the control (empty) NLc group according to one-way ANOVA and Tukey test; ¥Statistically significant 
difference (P , 0.05) with respect to the positive control group according to 1-way ANOVA and Tukey test.
Abbreviations: E:F ratio, extension:flexion ratio; VPA, valproic acid; NLC, nanostructured lipid carrier; MES, maximal electroshock.
Table 3 concentration of VPA in plasma and brain after administration of different formulations (n = 6)
Preparation Route Weight of rats 
(g) mean ± SD
Administrated  
dose (mg/kg)
Plasma 
concentration 
60 min after 
administration 
(μg/mL) mean ± SD
Brain concentration 
60 min after 
administration 
(μg/g) mean ± SD
Brain:plasma   
ratio after 
60 min
controla Intranasal 197.3 ± 11 – – – –
controla IP 178 ± 8 – – – –
NLc of VPA Intranasal 189 ± 20 4 7.96 ± 2.9 64.35 ± 5.7 8.4 ± 0.32
NLc of VPA IP 181 ± 12 20 11.35 ± 5.8 19.85 ± 8.5 1.65 ± 0.09
sodium VPA 
solution
Intranasal 188 ± 24 30b 3.87 ± 1.9 23.36 ± 8.3 6.77 ± 0.73
sodium VPA 
solution
IP 209 ± 9 150b 275.85 ± 39.5 112 ± 16 0.42 ± 0.02
Notes: acontrol contains all of the components of nanoparticles except VPA; bDosage is equivalent to VPA.
Abbreviations: VPA, valproic acid; NLc, nanostructured lipid carrier; IP, intraperitoneal.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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milieu in the intranasal cavity and facilitate their transport 
across the mucosal barriers.25 The observed responses of 
size (154 ± 16 nm), polydispersity index (0.2 ± 0.1), and 
zeta potential (−10 ± 0.5 mV) in Table 2 indicate that the 
nanoemulsions approached a monodisperse stable system and 
could deliver the drug effectively owing to large surface area. 
Intranasal is an efficacious route to deliver drugs (at small 
doses) rapidly and efficiently into the brain. Animal studies 
have shown that nanosized drug delivery   systems can enhance 
nose-to-brain delivery of drugs compared to equivalent 
drug solution formulations. Protection of the drug from 
degradation and/or efflux back into the intranasal cavity and 
blood may be the reason for this effect of nanoparticles.26 The 
nanoparticles and solid lipid nanoparticles (SLNs) with the 
size below 200 nm increased blood availability, eventually 
decreasing the time to pass the BBB and increasing uptake 
by the brain.27 Higher concentration of clozapine SLNs, with 
163 nm in size that were coated with Poloxamer 188, resulted 
in transport through the BBB by endocytosis.28 Study on 
nanoparticle transit into olfactory epithelium in mice showed 
that intranasally administered chitosan-coated   polystyrene or 
polysorbate-coated polystyrene nanoparticles of 100 nm can 
transport into olfactory epithelial cells.29 The use of intranasal 
route via olfactory nerve was also reported for brain targeting 
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Figure 2 comparison between the effect of sodium valproate solution positive control (150 mg/kg), NLcs of VPA (20 mg/kg), and control NLcs (without VPA) in IP route 
of administration on MES seizure protection which was assessed as the decrease of extension:flexion (E:F) ratio (n = 6).
Notes: *Statistically significant difference (P , 0.05) with respect to the control (empty) NLc group according to one-way ANOVA and Tukey test; ¥Statistically significant 
difference (P , 0.05) with respect to the positive control group according to 1-way ANOVA and Tukey test.
Abbreviations: E:F ratio, extension:flexion ratio; VPA, valproic acid; NLCs, nanostructured lipid carriers; MES, maximal electroshock; IP, intraperitoneal.
0
1
2
3
4
5
6
7
8
9
Time (min)
M
E
S
 
s
e
i
z
u
r
e
 
p
r
o
t
e
c
t
i
o
n
(
D
e
c
r
e
a
s
e
d
 
E
/
F
 
r
a
t
i
o
)
 
Nasal NLCs
I.P. positive control
120 30 15 60 90
Figure 3 comparison between MEs seizure protection effect of NLcs of VPA (4 mg/kg) in nasal route and sodium valproate solution (150 mg/kg) as positive control in 
IP route after different times of drug administration (P . 0.05) (n = 6). There is no statistical difference in any times according to independent t test.
Abbreviations: E:F ratio, extension:flexion ratio; VPA, valproic acid; NLCs, nanostructured lipid carriers; MES, maximal electroshock; IP, intraperitoneal.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
369
Brain delivery of VPA via intranasal administration of nanostructured lipid carriers
of carbamazepin,30 morphine,31 zolmitriptan,32 sumatriptan,33 
clonazepam, and nimodipine.34,35 All these reports showed 
promising transfer of adequate drug into the brain based on 
methods which are divided into four categories: nose–brain, 
nose–CSF, nose–brain/CSF, and pharmacodynamic studies.24 
There are a few studies monitoring pharmacologic effects as 
well as brain and/or blood levels of the active drug by using a 
large number of animals. It is evident that the majority of the 
studies in the area of nose–brain/CSF research do not meet 
the requirements as outlined in the theoretical study design. 
However, it is necessary to monitor drug levels within the 
blood or the brain to reveal the positive correlation between 
them.36 For this purpose, in the present study, the VPA concen-
tration is measured at the time of maximal protection against 
MES, leading to the minimal number of animals required. By 
this way, the number of animals to be killed was decreased 
significantly along with reaching the goal. As Figure 1 shows, 
there was a significant difference (P , 0.05) between 
protective effects of NLCs of VPA and control NLC in 15, 
30, 60, and 90 minutes after administration. This revealed 
that the drug might be at a higher concentration in the brain. 
Blasi et al showed that the drug   concentration of VPA in 
rats   sacrificed 20 and 90 minutes after treatment with (14C) 
sodium valproate (150 mg/kg) was high in blood and moderate 
in liver,   kidney, heart, and lung, but low in brain, fat, testis, and 
skeletal muscle.37 Figure 2 shows that MES seizure protection 
15, 60, and 90 minutes after IP injection of sodium valproate 
solution (150 mg/kg) was significantly different compared 
to the control NLC IP injection. Data in Table 3 show that 
intranasal administration of NLCs of VPA and sodium val-
proate solution causes higher drug concentration in the brain 
than in plasma. As Figure 1 shows, maximum MES seizure 
protection happened 60 minutes after intranasal administration 
of NLCs of VPA when the higher concentration than plasma 
was measured. It was assumed that VPA was transported 
from the brain to the circulating blood across the BBB via a 
carrier-mediated efflux transport process.38 Furthermore, the 
P-gp localized in the olfactory epithelium might prevent the 
drug to backflow through the membrane.36 For this reason, in 
the present study, Poloxamer was added to our formulation 
to prevent the drug efflux from the membrane and to result 
in higher drug concentrations within the brain as it was 
shown in previous studies.27 Friese et al used nanoparticles 
of a novel glutamate receptor antagonist drug coated with 
polysorbate 80 and increased the duration of anticonvulsive 
activity and the CNS availability of the drug.39 As it is shown 
in Figures 3 and 4, the results of protective effect of NLCs of 
VPA in intranasal route are comparable with systemic route. 
The intranasal route is an alternative to systemic route for 
delivery of many drugs, and most of the research articles 
compared them with each other.40 It was shown that olfactory 
bulb efferent projections may act as important sites of action 
for VPA because this projection might be involved in seizure 
generalization.13 Furthermore, intranasal administration of 
VPA seems to accelerate binding of the VPA to the olfactory 
bulb and improving its efficacy even with smaller dosage of 
administration in intranasal route. Determination of effective 
brain concentrations is important for the interpretation of 
data on valproate. It should be noted that the effective brain 
concentration in rodents is much higher than respective doses 
in humans, because of the higher elimination rate of the drug. 
However, brain:plasma concentration ratio of valproate is 
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almost equal to the respective ratio in humans.13 The results 
of this study showed that brain:plasma concentration ratio 
increased to about 20 times after intranasal administration of 
NLCs of VPA compared to IP administration.
Conclusion
The present study clearly demonstrated that intranasal 
administration of nanostructures of VPA in rats is a suitable 
method to maintain the effect of VPA with much higher 
brain:plasma concentration ratio. The same protective effect 
as systemic administration was seen with much lower doses. 
Intranasal administration may represent a remarkable deliv-
ery route for targeting to the brain with an appropriate dosage 
form design. Further studies are required to evaluate whether 
this dosage form of VPA is clinically beneficial.
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